[EN] IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS [FR] DÉRIVÉS IMIDAZO[1,2-A]PYRIDINE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
[EN] IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS [FR] DÉRIVÉS IMIDAZO[1,2-A]PYRIDINE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
申请人:Trabanco-Suarez Andres Avelino
公开号:US08785486B2
公开(公告)日:2014-07-22
The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
申请人:Trabanco-Suarez Andres Avelino
公开号:US20110009441A1
公开(公告)日:2011-01-13
The present invention relates to novel compounds, in particular novel imidazo[1,2-a]piridine derivatives according to Formula (I). The compounds according to the invention are positive allosteric modulators of metabotropic receptors-sub-type 2 (‘mGluR2’) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.
[EN] IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS IMIDAZO[1,2-A]PYRIDINE ET LEUR UTILISATION COMME MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
申请人:ORTHO MCNEIL JANSSEN PHARM
公开号:WO2009062676A3
公开(公告)日:2009-09-03
Scaffold hopping from pyridones to imidazo[1,2-a]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor
作者:Gary Tresadern、Jose María Cid、Gregor J. Macdonald、Juan Antonio Vega、Ana Isabel de Lucas、Aránzazu García、Encarnación Matesanz、María Lourdes Linares、Daniel Oehlrich、Hilde Lavreysen、Ilse Biesmans、Andrés A. Trabanco
DOI:10.1016/j.bmcl.2009.11.008
日期:2010.1
Imidazo[1,2-a] pyridines were identidied via their shape and electrostatic similarity as novel positive allosteric modulators of the metabotropic glutamate 2 receptor. The subsequent synthesis and SAR are described. Potent, selective and metabolically stable compounds were found representing a promising avenue for current further studies. (C) 2009 Elsevier Ltd. All rights reserved.